DECLARATION FOR NON-PROVISIONAL PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office in ssand citizenship are as stated below at 201 et seq. beneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled COMPOSITIONS AND METHODS FOR TUMOR-TARGETED DELIVERY OF EFFECTOR MOLECULES

and f	for which a patent application:
\boxtimes	is attached hereto and includes the Preliminary Amendment filed herewith. (if applicable)
	was filed in the United States on as Application No. (for declaration not accompanying application)
	with amendment(s) filed on (if applicable)
	was filed as PCT international Application No. on and was amended under PCT Article 19 on (if applicable)
	eby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any idment referred to above
Logic	nowledge the duty to disclose information known to me to be material to natentability as defined in Title 37. Code of Federal

Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION						
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED			
			YES 🗆	NO □		
			YES 🗆	NO 🗆		

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NUMBER	FILING DATE	
60/157,637	October 4, 1999	
60/157,581	October 4, 1999	
60/157,500	October 4, 1999	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information known to me which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

NON-PROVISIONAL	FILING DATE	STATUS			
APPLICATION SERIAL NO.		PATENTED	PENDING	ABANDONED	
09/645,415	August 24, 2000		X		

for use only when the application is assigned to a company, partnership or other organization.

(1)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	FULL NAME	LAST NAME	FIRST NAME	MIDDLE NAME	
	OF INVENTOR	*King	Ivan	C.	
2 0	RESIDENCE & CITIZENSHIP	спу New Haven	STATE OR FOREIGN COUNTRY Connecticut	COUNTRY OF CITIZENSHIP U.S.A.	
1	POST OFFICE ADDRESS	STREET 65 Blue Hills Road	спу New Haven	STATE OR COUNTRY Connecticut	ZIP CODE 06473
		SIGNATURE OF INVENTOR 201		December 9, 2003	

Express Mail No.: EL 501 636 931 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bermudes et al.

Serial No.: 09/645,415

Group Art Unit: 1614

Filed: August 24, 2000

Examiner: To Be Assigned

For:

COMPOSITIONS AND METHODS FOR

TUMOR-TARGETED DELIVERY OF

EFFECTOR MOLECULES

Attorney Docket No.: 8002-059-999

REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

Vion Pharmaceuticals, Inc., having a place of business at Four Science Park, New Haven, Connecuticut 06511, and owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application by virtue of an Assignment, a copy of which is attached hereto as Exhibit A, hereby revokes all previous powers of attorney and appoint S. Leslie Misrock (Reg. No. 18872), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebel (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No.

35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), Alan Tenenbaum (Reg. No. 34939), Michael J. Lyons (Reg. No. 37,386), Garland T. Stephens (Reg. No. 37,242) and William J. Sipio (Reg. No. 34,514), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them its attorneys, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, N.Y. 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

By:

Terrence Doyle

Vice President of

Respectfully submitted,

Research and Development Chief Scientific Officer VION PHARMACEUTICALS, INC.